Appili Therapeutics Inc. (APLI.TO)

CAD 0.04

(-12.5%)

Net Debt Summary of Appili Therapeutics Inc.

Appili Therapeutics Inc.'s latest annual net debt in 2023 was 8.09 Million CAD , up 55.6% from previous year.
Appili Therapeutics Inc.'s latest quarterly net debt in 2024 Q1 was 9.75 Million CAD , up 20.52% from previous quarter.
Appili Therapeutics Inc. reported annual net debt of 5.19 Million CAD in 2022, up 408.36% from previous year.
Appili Therapeutics Inc. reported annual net debt of -1.68 Million CAD in 2021, up 83.19% from previous year.
Appili Therapeutics Inc. reported quarterly net debt of 8.09 Million CAD for 2023 Q4, up 9.19% from previous quarter.
Appili Therapeutics Inc. reported quarterly net debt of 7.6 Million CAD for 2023 Q2, up 6.14% from previous quarter.

Annual Net Debt Chart of Appili Therapeutics Inc. (2023 - 2016)

Historical Annual Net Debt of Appili Therapeutics Inc. (2023 - 2016)

Year	Net Debt	Net Debt Growth
2023	8.09 Million CAD	55.6%
2022	5.19 Million CAD	408.36%
2021	-1.68 Million CAD	83.19%
2020	-10.03 Million CAD	-5.53%
2019	-9.5 Million CAD	-120.91%
2018	-4.3 Million CAD	6.67%
2017	-4.61 Million CAD	-406.34%
2016	-910.48 Thousand CAD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	9.75 Million CAD	20.52%
2023 Q4	8.09 Million CAD	9.19%
2023 Q2	7.6 Million CAD	6.14%
2023 Q1	7.16 Million CAD	37.84%
2023 Q3	7.4 Million CAD	-2.6%
2023 FY	8.09 Million CAD	55.6%
2022 FY	5.19 Million CAD	408.36%
2022 Q2	2.98 Million CAD	1033.56%
2022 Q3	4.01 Million CAD	34.3%
2022 Q4	5.19 Million CAD	29.53%
2022 Q1	-320.16 Thousand CAD	81.01%
2021 Q1	-8.28 Million CAD	17.38%
2021 FY	-1.68 Million CAD	83.19%
2021 Q4	-1.68 Million CAD	73.53%
2021 Q3	-6.37 Million CAD	-3.02%
2021 Q2	-6.18 Million CAD	25.39%
2020 Q4	-10.03 Million CAD	29.35%
2020 Q3	-14.19 Million CAD	-19.87%
2020 Q1	-4.52 Million CAD	52.43%
2020 FY	-10.03 Million CAD	-5.53%
2020 Q2	-11.84 Million CAD	-161.95%
2019 Q2	-2.03 Million CAD	35.94%
2019 Q1	-3.17 Million CAD	26.21%
2019 FY	-9.5 Million CAD	-120.91%
2019 Q4	-9.5 Million CAD	-580.64%
2019 Q3	-1.39 Million CAD	31.33%
2018 Q4	-4.3 Million CAD	-16.68%
2018 FY	-4.3 Million CAD	6.67%
2018 Q3	-3.68 Million CAD	0.0%
2018 Q1	5.75 Million CAD	224.77%
2017 Q4	-4.61 Million CAD	0.0%
2017 FY	-4.61 Million CAD	-406.34%
2016 FY	-910.48 Thousand CAD	0.0%

Peer Net Debt Comparison of Appili Therapeutics Inc.

Name	Net Debt	Net Debt Difference
Eupraxia Pharmaceuticals Inc.	-11.72 Million CAD	169.019%
Helix BioPharma Corp.	-1.08 Million CAD	848.415%
Microbix Biosystems Inc.	-4.96 Million CAD	263.074%
Medicenna Therapeutics Corp.	-16.98 Million CAD	147.641%
Satellos Bioscience Inc.	-22.06 Million CAD	136.663%
Oncolytics Biotech Inc.	-31.11 Million CAD	126.005%
Sernova Corp.	-8.58 Million CAD	194.231%